Gilead
Gilead Sciences has announced the promotion of Andrew Cheng to Senior VP, Development Operations. He will report to Norbert Biscofberger, Chief Scientific Officer.
Cheng has worked at Gilead since 1999, most recently as CP, Clinical Research, where he oversaw clinical development for the company's HIV/AIDS programme. Before joining Gilead, he trained in medicine at the University of California, Los Angeles and received a PhD in Cellular and Molecular Biology from Columbia University.
"Over the past decade, Andrew has played a key leadership role overseeing multiple clinical programs, including pivotal studies supporting the approval of our HIV medications and clinical program design for our investigational HIV candidate, elvitegravir, and our novel pharmacoenhancer, GS 9350," said Bischofberger.
"With a growing number of programmes currently in our research and development pipeline and the increasing complexity of our business, Andrew's new role will help us maintain an efficient and cost-effective approach to development, enhancing collaboration across our four therapeutic areas and ensuring we can advance promising candidates as quickly as possible."
(Image: Bill Brooks)